Legend Biotech said CEO Ying Huang resigned without naming a permanent replacement, and appointed Carvykti head Alan Bash as interim CEO. The move extends recent volatility around the company’s leadership and operational stability. Legend’s filing notes that Huang’s departure was not tied to disagreements over operations, policies, or financial statement controls, and he will remain as an advisor through August. Bash’s initial focus is on continuity across the commercial and development portfolio tied to Carvykti. The announcement matters for stakeholders because leadership transitions can affect execution cadence for late-stage development, manufacturing scale-up, and payor contracting in competitive cell therapy markets.